Miriam Wiese-Posselt

Dr. Miriam Wiese-Posselt


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2007 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
DHDagmar Heuck
Dagmar Heuck
ADAndreas Draeger
Andreas Draeger
MMMartin Mielke
Martin Mielke
WWWolfgang Witte
Wolfgang Witte
OHOsamah Hamouda
Osamah Hamouda
Background. Skin infections due to Staphylococcus aureus have recently become a public concern, mainly because of emerging resistance against widely

12 May 2022 in Mycoses
Verified
Journal Article
Open access
AAAlexander Maximilian Aldejohann
Alexander Maximilian Aldejohann
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
PGPetra Gastmeier
Petra Gastmeier
OKOliver Kurzai
Oliver Kurzai
Candida auris was first described as a yeast pathogen in 2009. Since then, the species has emerged worldwide. In contrast to most other Candida spp., C. auris frequently exhibits multi‐drug resistance and is readily transmitted in hospital settings. While most detections so far are from colonised patients, C. auris does cause superficial and life‐threatening invasive infections. During management of the first documented C. auris transmission in a German hospital, experts from the National Reference Centers for Invasive Fungal Infections (NRZMyk) and the National Reference Center for Surveillance of Nosocomial Infections screened available literature and integrated available knowledge on infection prevention and C. auris epidemiology and biology to enable optimal containment. Relevant recommendations developed during this process are summarised in this guidance document, intended to assist in management of C. auris transmission and potential outbreak situations. Rapid and effective measures to contain C. auris spread require a multi‐disciplinary approach that includes clinical specialists of the affected unit, nursing staff, hospital hygiene, diagnostic microbiology, cleaning staff, hospital management and experts in diagnostic mycology / fungal infections. Action should be initiated in a step‐wise process and relevant interventions differ between management of singular C. auris colonised / infected patients and detection of potential C. auris transmission or nosocomial outbreaks.

24 April 2022 in Mycoses
Verified
Journal Article
Open access
CHCarl Hinrichs
Carl Hinrichs
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
BGBarbara Graf
Barbara Graf
CGChristine Geffers
Christine Geffers
BWBeate Weikert
Beate Weikert
OKOliver Kurzai
Oliver Kurzai
Background: Candida auris a frequently multidrug‐resistant yeast species that poses a global health threat due to its high potential for hospital outbreaks. While C. auris has become endemic in parts of Asia and Africa, transmissions have so far rarely been reported in Western Europe except for Great Britain and Spain. We describe the first documented patient‐to‐patient transmission of C. auris in Germany in a COVID‐19 intensive care unit (ICU) and infection control measures implemented to prevent further spread of the pathogen.Methods: Identification of C. auris was performed by MALDI‐TOF and confirmed by internal transcribed spacer (ITS) sequencing. Antifungal susceptibility testing was carried out. We conducted repeated cross‐sectional examinations for the presence of C. auris in the patients of the affected ICU and investigated possible routes of transmission.Results: The index patient had been transferred to Germany from a hospital in Northern Africa and was found to be colonised with C. auris. The contact patient developed C. auris sepsis. Infection prevention and control (IPC) measures included strict isolation of the two C. auris patients and regular screening of non‐affected patients. No further case occurred during the subsequent weeks. Reusable blades used in video laryngoscope‐guided intubation were considered as the most likely vehicle of transmission.Conclusions: In view of its high risk of transmission, vigilance regarding C. auris colonisation in patients referred from endemic countries is crucial. Strict and immediate IPC measures may have the potential to prevent C. auris outbreaks.

24 March 2006 in Vaccine
Verified
Journal Article
Closed access
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
KLKatrin Leitmeyer
Katrin Leitmeyer
OHOsamah Hamouda
Osamah Hamouda
NBNikolaus Bocter
Nikolaus Bocter
IZIris Zöllner
Iris Zöllner
AAAndrea Ammon
Andrea Ammon

19 May 2017 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
ASAnette Siedler
Anette Siedler
AMAnnette Mankertz
Annette Mankertz
ASAndreas Sauerbrei
Andreas Sauerbrei
HHHartmut Hengel
Hartmut Hengel
CPChristina Poethko-Müller
Christina Poethko-Müller
In 2004, universal childhood varicella vaccination was introduced in Germany. We aimed to determine the age-specific prevalence of anti-varicella zoster virus (VZV) IgG-antibodies among children in the pre-varicella vaccine era in Germany, to identify factors associated with VZV seropositivity, and to assess the suitability of a commercially available ELISA for VZV seroepidemiological studies by comparing it with an in-house fluorescent antibody to membrane antigen test (FAMA) as the gold standard. Serum samples of 13,433 children and adolescents aged 1–17 years included in the population-based German Health Interview and Examination Survey for Children and Adolescents (KiGGS; conducted 2003–2006) were tested for anti-VZV IgG by ELISA. All samples with equivocal ELISA results and a random selection of ELISA-negative and -positive samples were tested by FAMA. Statistical analyses were conducted using a weighting factor adjusting the study population to the total population in Germany. Seroprevalences were calculated as percentages (%) with a 95% confidence interval (CI). Odds ratios (OR) were computed by multivariate logistic regression to determine the association between socio-demographic factors and VZV seropositivity. The VZV seropositivity rate was 80.3% (95% CI: 79.3–81.3) in varicella-unvaccinated children and adolescents. VZV seropositivity rates differed significantly between age groups up to age 6 years, but not by gender. Of 118 retested serum samples with an equivocal ELISA result, 45.8% were FAMA-positive. The proportion of samples tested as false-negative in by ELISA varied by age group: 2.6% in children aged 1–6 and 9% in children aged 7–17 years. Multivariate analyses showed that age, having older siblings, and early daycare start were associated with seropositivity in preschoolers; migration background reduced the chance of VZV seropositivity in schoolchildren (OR: 0.65; 0.43–0.99) and adolescents (OR: 0.62; 0.4–0.97). In the pre-varicella vaccine era, most children in Germany contracted varicella by age six. Schoolchildren with a migration background and children without siblings have an increased risk of being VZV seronegative and should be targeted for catch-up vaccination, if they have no history of chickenpox. ELISAs are suitable for use in population-level serosurveys on VZV, but samples with equivocal ELISA results should be retested by FAMA.

22 April 2010 in Eurosurveillance
Verified
Journal Article
Open access
MWMiriam Wiese-Posselt
Miriam Wiese-Posselt
WHW Hellenbrand
W Hellenbrand
In July 2009, the German Standing Committee on Vaccination (STIKO) modified its recommendations for varicella and pertussis vaccination, based on newly available data on disease epidemiology, vaccine effectiveness (VE) and safety, and an evaluation of the feasibility of the recommended immunisation strategy. The recommendation for varicella vaccine now includes a routine two-dose schedule with the administration of the first dose at the age of 11 to 14 months and the second dose at the age of 15 to 23 months, with a minimum interval of four weeks between these doses. Furthermore, STIKO recommended adding a one-time pertussis booster to the adult vaccination schedule to expand the cocoon strategy in place since 2004. The recommendation of a booster vaccination with an acellular pertussis vaccine every 10 years for persons employed in the care of pre-school children and for healthcare personnel in paediatric, gynaecologic and obstetric health facilities was extended to persons employed in schools and in other institutions caring for older children, and to all healthcare personnel. These recommendations were based on available epidemiological data showing an increase in incidence from 7-10 cases per 100,000 inhabitants in 2002-2004 to over 30 by 2007. Moreover, the high burden of pertussis in infants at 94 hospitalised cases per 100,000 infants in 2007 suggested that the previous cocoon strategy was insufficient.